How to buy Kalvista Pharmaceuticals stock (KALV)

Kalvista Pharmaceuticals is a biotechnology business based in the US. Kalvista Pharmaceuticals shares (KALV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.76 – an increase of 8.28% over the previous week. Kalvista Pharmaceuticals employs 150 staff and has a trailing 12-month revenue of around $3.8 million.

Our top picks for where to buy Kalvista Pharmaceuticals stock

Buy Kalvista Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kalvista Pharmaceuticals stock price (NASDAQ: KALV)

Use our graph to track the performance of KALV stocks over time.

Kalvista Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$8.76
52-week range	$8.07 - $16.88
50-day moving average more info button	$10.57
200-day moving average more info button	$11.75
Wall St. target price	$27.57
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.68

Is it a good time to buy Kalvista Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kalvista Pharmaceuticals price performance over time

Historical closes compared with the close of $8.76 from 2024-12-24

1 week (2024-12-19)	8.28%
1 month (2024-11-26)	-12.22%
3 months (2024-09-26)	-12.40%
6 months (2024-06-26)	-22.55%

1 year (2023-12-26)	-25.95%
2 years (2022-12-23)	71.43%
3 years (2021-12-23)	14.44
5 years (2019-12-26)	17.59

Kalvista Pharmaceuticals financials

Revenue TTM	$3.8 million
Gross profit TTM	$-80,276,000
Return on assets TTM	-53.94%
Return on equity TTM	-90.84%
Profit margin	0%
Book value	$4.86
Market Capitalization more info button	$418.1 million

TTM: trailing 12 months

Kalvista Pharmaceuticals share dividends

We're not expecting Kalvista Pharmaceuticals to pay a dividend over the next 12 months.

Have Kalvista Pharmaceuticals's shares ever split?

Kalvista Pharmaceuticals's shares were split on a 1:14 basis on 21 November 2016 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kalvista Pharmaceuticals shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Kalvista Pharmaceuticals shares which in turn could have impacted Kalvista Pharmaceuticals's share price.

Kalvista Pharmaceuticals share price volatility

Over the last 12 months, Kalvista Pharmaceuticals's shares have ranged in value from as little as $8.07 up to $16.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kalvista Pharmaceuticals's is 0.913. This would suggest that Kalvista Pharmaceuticals's shares are less volatile than average (for this exchange).

Kalvista Pharmaceuticals overview

KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Kalvista Pharmaceuticals is owned by insiders or institutions?
Currently 1.357% of Kalvista Pharmaceuticals shares are held by insiders and 110.285% by institutions. How many people work for Kalvista Pharmaceuticals?
Latest data suggests 150 work at Kalvista Pharmaceuticals. When does the fiscal year end for Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals's fiscal year ends in April. Where is Kalvista Pharmaceuticals based?
Kalvista Pharmaceuticals's address is: 55 Cambridge Parkway, Cambridge, MA, United States, 02142 What is Kalvista Pharmaceuticals's ISIN number?
Kalvista Pharmaceuticals's international securities identification number is: US4834971032 What is Kalvista Pharmaceuticals's CUSIP number?
Kalvista Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 141384107